Skip to main content
. Author manuscript; available in PMC: 2012 Dec 1.
Published in final edited form as: Anesthesiology. 2011 Dec;115(6):1316–1327. doi: 10.1097/ALN.0b013e3182315eb2

Figure 5.

Figure 5

Clinical relevance of CYP2D6 genotype on β-blocker treatment. Poor CYP2D6 metabolizers experience a greater reduction in heart rate (a) and a higher risk of bradycardia when treated with metoprolol.

HR = heart rate; PM = poor metabolizer.

Reprinted with permission from Macmillan Publishers Ltd.: [Clinical Pharmacology & Therapeutics] Rau T et al., Impact of the CYP2D6 Genotype on the Clinical Effects of Metoprolol: A Prospective Longitudinal Study 2009; 85: 269–72.